Bone Therapeutics extends Kasios collaboration
Bone Therapeutics, the bone cell therapy company addressing high unmet medical needs in the field of bone fracture repair and bone fracture prevention, have announced the extension of its collaboration with Kasios, a synthetic bone substitute specialist, to develop next generation spinal fusion integrated products.
Under the new collaboration, the companies aim to combine Bone Therapeutics’ ALLOB® cells with Kasios’ spinal fusion cage containing a 3D-bioprinted synthetic matrix (or ‘waffle’). The goal of this combined product is to simplify the surgical procedure and accelerate the fusion process.
Spinal fusion is considered to be the gold standard for treating a broad spectrum of degenerative spine disorders, including degenerative disc disease, to relieve pain and improve function. Although the procedure is routine, failure to achieve fusion between the vertebrae is quite common.
Bone Therapeutics aims to accelerate the fusion process and increase success rates of the surgery using its allogeneic bone cell therapy product, ALLOB®.
Kasios specialises in the development of spinal fusion cages and synthetic bone substitutes. In a previous collaboration, the companies successfully combined Kasios’ synthetic micro-granules with ALLOB cells, and preclinical studies showed that the combination resulted in increased bone formation. In the next step, the biocompatibility of the matrix with ALLOB will be tested in preclinical studies.
The companies’ ultimate goal is to provide an integrated ready-to-use product for surgeons that simplifies the procedure and reduces operation time.
Enrico Bastianelli, CEO of Bone Therapeutics, said: “We are delighted to extend our collaboration with Kasios, following encouraging results from the work we have completed so far. We believe that combining our products offers potential for an exciting and more convenient alternative for surgeons in spinal fusion procedures and we look forward to continuing to work together.”
Source: Business Wire